By Fineline Cube 
Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its BroncAblate pulmonary radiofrequency ablation (RFA) system console.
Innovative System Features
The newly approved console, when used in conjunction with the BroncAblate disposable pulmonary RFA catheter approved in April 2025, forms the world’s first interventional device for transbronchial RFA of lung tumors. The system is equipped with real-time monitoring of target tissue temperature and impedance, providing visualized control and intelligent power adjustment to enhance the precision and safety of ablation procedures.
Clinical Application
The product delivers stable radiofrequency energy to the core of pulmonary lesions via a transbronchial approach. This method achieves tumor tissue inactivation with minimal invasiveness, representing a significant advancement in the treatment of lung tumors.-Fineline Info & Tech